CLDX

Celldex Therapeutics, Inc.

7 filings tracked

healthcarebiotechnologySMALL ($300M-2B)

Signal Magnitude Chart

bullish

bearish

neutral

Signal Timeline

bullishMay 7

Secured $323.9 million in net proceeds from an April 2026 public offering.

capital raise

90%

bearishMay 7

Operating loss increased 35% year-over-year to $84.4 million.

margin compression

70%

bearishMay 7

Contract and grants revenue declined 98% year-over-year.

earnings miss

50%

bullishMay 7

Secured $323.9 million in net proceeds from an April 2026 public offering.

capital raise

90%

bearishMay 7

Operating loss increased 35% year-over-year to $84.4 million.

margin compression

70%

bearishMay 7

Contract and grants revenue declined 98% year-over-year.

earnings miss

50%

bullishMay 7

Secured $323.9 million in net proceeds from an April 2026 public offering.

capital raise

90%

bearishMay 7

Operating loss increased 35% year-over-year to $84.4 million.

margin compression

70%

bearishMay 7

Contract and grants revenue declined 98% year-over-year.

earnings miss

50%

bullishMay 7

Secured $323.9 million in net proceeds from an April 2026 public offering.

capital raise

90%

bearishMay 7

Operating loss increased 35% year-over-year to $84.4 million.

margin compression

70%

bearishMay 7

Contract and grants revenue declined 98% year-over-year.

earnings miss

50%

bullishMay 7

Secured $323.9 million in net proceeds from an April 2026 public offering.

capital raise

90%

bearishMay 7

Operating loss increased 35% year-over-year to $84.4 million.

margin compression

70%

bearishMay 7

Contract and grants revenue declined 98% year-over-year.

earnings miss

50%

bullishMay 7

Secured $323.9 million in net proceeds from an April 2026 public offering.

capital raise

90%

bearishMay 7

Operating loss increased 35% year-over-year to $84.4 million.

margin compression

70%

bearishMay 7

Contract and grants revenue declined 98% year-over-year.

earnings miss

50%

bullishMay 7

Secured $323.9 million in net proceeds from an April 2026 public offering.

capital raise

90%

bearishMay 7

Operating loss increased 35% year-over-year to $84.4 million.

margin compression

70%

bearishMay 7

Contract and grants revenue declined 98% year-over-year.

earnings miss

50%

Filing History

10-QMay 7, 2026

The Q1 2026 filing reveals a company at a critical juncture, balancing massive capital inflows against accelerating operational losses. The April public offering has provided a necessary runway, but the underlying financial trend shows a business that is becoming increasingly expensive to run as it nears the finish line. The trade-off for investors is now a matter of timing and clinical confidence. The overall impact of the filing is a shift in the risk profile from 'funding risk' to 'execution risk.' While the balance sheet is no longer the primary concern, the concentration of value in the barzolvolimab program creates a high-stakes environment. The market will likely remain volatile until the Q4 2026 topline data provides clarity on whether the company's capital-intensive bet on mast cell depletion will yield a commercial success.